AstraZeneca Takes Five: DTC Study Finds Five Risks Per Ad Is Optimal For Recall
Executive Summary
An AstraZeneca study on consumer communication through direct-to-consumer television advertisements identifies five risks as the optimal number to include in order to ensure consumer recall of safety information
You may also be interested in...
Rx Safety Communication In Face Of Uncertainty, Multiple Risks, To Be Examined By FDA Panel
FDA’s Risk Communication Advisory Committee will delve into research on communicating uncertainty and how individuals perceive risk and seek information when confronted with multiple risks, during a June 29 meeting.
Rx TV Ads To Get FDA Study On How Visual Cues May Distract From Audio Risks
Data collection in an FDA study of how the audio, visual and textual components of a television ad affect a viewer's intake of information and perception of a drug's risks and benefits is expected to begin in May 2008
Rx TV Ads To Get FDA Study On How Visual Cues May Distract From Audio Risks
Data collection in an FDA study of how the audio, visual and textual components of a television ad affect a viewer's intake of information and perception of a drug's risks and benefits is expected to begin in May 2008